



Journal of Pharmacovigilance and Drug Safety

An Official Publication of Society of Pharmacovigilance, India.

Case Series

Drug Safety Alerts issued by Indian Pharmacopeia Commission, National Coordination Centre January - June 2022

The preliminary analysis of Adverse Drug Reactions (ADR) from the PvPI database reveals that following suspected drug are associated with the ADRS reported by PvPI during January to June 2022 as given below,

Consumer(<http://www.ipc.gov.in>), through Android Mobile App “ADR PvPI App” and Pvp Helpline No. 1800-180-3024(Toll Free) or through nearby Adverse Drug Reaction Monitoring Centre (AMC).

IPC is a WHO-Collaborative Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services in SEARN.

S. No	Suspected Drug	Indication	Adverse Drug b Reaction
1.	Ibuprofen	For the treatment of chronic arthritic disorders and painful musculoskeletal Conditions.	Fixed Drug Eruption
2.	Losartan	For the treatment of hypertension	Muscle Spasm
3.	Cephalosporin Class	Cephalosporin are beta-lactam antimicrobials used to manage a wide range of infections from Gram-positive and Gram-negative bacteria	Fixed Drug Eruption

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of these ADRs associated with the use of the suspected drugs. If such reaction are encountered, please reported to the NCC-PvPI, IPC by filling of suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting form for

Compiled by **Bipin Prakash Tamta (Pharmacovigilance Associate)** under the supervision of **Prof. Mirza Atif Beg (Coordinator) & Prof. Shalu Bawa (Deputy Coordinator), ADR Monitoring Centre (PvPI), Department of Pharmacology, Shree Guru Ram Rai institute of Medical & Health Science & SMI Hospital, Dehradun, Uttarakhand.**

REFERENCE

- [http:// www.ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-cn/416-drug-safety-alerts.htm](http://www.ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-cn/416-drug-safety-alerts.htm)

Access this article online	
Website: www.journalofsopi.com	For Reprints
DOI: 10.21276/jpds.2020.19.01.06	Contact at editorjournalofsopi@gmail.com